<p>Ovarian cancer is one of the most common gynecological malignancies and has the highest mortality rate among gynecological cancers. Its difficulties in diagnosis, high mortality rate, high recurrence rate, and poor prognosis, have always been a major obstacle for researchers. Gene therapy, a revolutionary medical approach, can correct genetic defects to treat intractable diseases, enable personalized medicine, and boost medical research, thus holding great promise for reshaping healthcare. siRNA interference technology has become one of the key directions in drug research field due to its advantages of high efficiency, high specificity, and low toxicity. And the development of new targeted drugs using siRNA interference technology has attracted significant attention. However, siRNA needs to overcome the vascular barrier, achieve intracellular uptake and escape from lysosomes, while also avoiding degradation by nucleases. Fortunately, the emergence of nanomaterials has provided new insights and strategies for siRNA drug delivery. Herein, we review the current advances in nanoparticle-mediated siRNA delivery strategies, as well as the application of siRNA-loaded nanomaterials in the diagnosis and therapy of ovarian cancer.</p><p></p>